Healthcare, Pharmaceuticals and Biotech

Life Sciences Week Webcast: Key Insights and Trends – The Current and Future State of the Industry

As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, we will be joined by experts from within Kroll and the wider industry to who will look ahead to what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.

People

Andreas Chrysostomou

Managing Director
Valuation Advisory

New York

Andreas Chrysostomou

Brooks Dexter

Managing Director
Healthcare MA

Los Angeles

Brooks Dexter

Nick Beaton

Business Development Manager
Compliance Risk and Diligence

London

Nick Beaton

Brian Lapidus

Managing Director and Global Breach Notification Leader
Cyber Risk

Nashville

Brian Lapidus

Tom Everett Heath

Managing Director and Global Practice Leader
Business Intelligence and Investigations

London

Tom Everett Heath

Jason N. Smolanoff

President, Cyber Risk

Jason N. Smolanoff

Jason Smolanoff is a senior managing director at Kroll.

Jason N. Smolanoff

Nick Doyle

Managing Director and Regional Leader, EMEA
Security Risk Management

London

Nick Doyle

Kroll helps organizations in the healthcare, pharmaceuticals and biotechnology sectors address complex business challenges related to governance, risk and transparency.

Pharmaceutical, healthcare, biotech and medical device companies face a challenging, competitive health landscape. Pricing pressures, scientific breakthroughs, expanding demand for healthcare access and emerging digital and analytic capabilities push companies to explore unconventional business models and build value-based customer relationships.

Underpinning these dynamics is the uncertainty created by a post-COVID-19 environment. The implications have been far-reaching and will likely impact the entire life science ecosystem. While companies need to be aware of the risks to their organization, Kroll understands the complexity of these challenges and works with clients worldwide to drive progress, navigate new opportunities and manage risk.

Our life sciences specialists bring practical, in-depth experience to healthcare and life sciences companies, including consumer health, medical devices, diagnostics and pharmaceuticals. We help our clients address their most pressing challenges in in the areas of valuation, expert services, investigations, cyber risk, corporate finance, security, restructuring, legal and business solutions, data analytics, due diligence and regulatory compliance.

Please join us June 21-24 for Kroll’s Life Sciences week. We will bring together our leading experts and industry leaders to set the roadmap for a new era where pharma, patients, providers and society are united in their efforts of greater value.

We will provide insights for pharmaceutical and life sciences professionals on operational risk, compliance, supply chain, health and safety and technology, including:

“Deep-dive interviews” with industry leaders demonstrating examples on their approach
Inherent risks impacting the industry
Case studies on how the life science industry has managed to adapt to market changes
Commentary on the latest regulation, technology developments and industry trends
Panel discussions that cover the most important challenges due to the impact of COVID-19

Other Areas We Can Help

Valuation Advisory

Valuation and consulting for financial reporting, federal, state and local tax, investment and risk management purposes.

Valuation Advisory

Healthcare MA

Healthcare expertise for middle-market M&A transactions.

Healthcare MA

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Transaction Advisory Services

Tax Services

Built upon the foundation of its renowned valuation business, Duff & Phelps' Tax Services practice follows a detailed and responsive approach to capturing value for clients.

Tax Services